Spondyloarthritis & psoriatic arthritis
Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis
Authors' conclusion
Bimekizumab demonstrated sustained improvements in health status and work productivity to year 3 across axSpA and PsA.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) who completed phase III trials of SC bimekizumab 160 mg every 4 weeks and entered open-label extensionsobserved cases
- Participants
- 586 vs 1,112
- Comparison
- Bimekizumab 160 mg every 4 weeks, in patients originally randomised to placebo or bimekizumab, through year 3
- axSpAn = 586
- PsAn = 1,112
Methodological detailsopen-label extension, observed cases
- Open-label extension
- Observed cases
Primary result
As reported in the abstract
Change in EQ VAS (0-100), mean improvement from baseline · year 3
axSpA
20.2-21.3
mean · points
PsA
17.1-17.3
mean · points
Further findings
| Outcome | axSpA | PsA |
|---|---|---|
| Clinically meaningful improvement in work impairment · year 3 | 74.2-81.1% | 71.2- 71.3% |
| Acceptable work state (WPAI-SHP presenteeism < 40%) · year 3 | 83.7-84.2% | 84.1-87.2% |
| Annualized productivity cost savings, US (US dollars) · year 3 | $22,012.14-22,549.32 US dollars | $13,327.60-16,428.25 US dollars |
Annualized productivity cost savings, US (US dollars) · year 3
- Similar trends were observed in Europe and Japan
Original publication
Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →